Yogurt Intake-Colorectal Cancer Link Differs by Abundance of Bifidobacterium
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 25, 2025 -- The association of long-term yogurt intake with colorectal cancer incidence seems to differ by the abundance of tumor tissue Bifidobacterium, according to a study published online Feb. 12 in Gut Microbes.
Satoko Ugai, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues utilized the prospective cohort incident-tumor biobank method and resources of two prospective cohort studies to examine whether long-term yogurt intake is associated with colorectal cancer incidence differentially by tumor subgroups according to the amount of tissue Bifidobacterium.
The researchers documented 3,079 incident colorectal cancer cases, including 1,121 with available tissue Bifidobacterium data, during follow-up of 132,056 individuals. There was a difference in the association between long-term yogurt intake and colorectal cancer incidence based on the abundance of Bifidobacterium (P heterogeneity = 0.0002). Multivariable-adjusted hazard ratios were 0.80 (95 percent confidence interval, 0.50 to 1.28) and 1.09 (95 percent confidence interval, 0.81 to 1.46) in individuals who consumed two or more servings/week versus less than one serving/month for Bifidobacterium-positive and Bifidobacterium-negative tumors, respectively. In a subgroup analysis of proximal colon cancer, this differential association was also seen (P heterogeneity, 0.018).
"Our findings suggest that long-term yogurt intake may lower the incidence of Bifidobacterium-positive proximal colorectal cancer (but not Bifidobacterium-negative subtype)," the authors write. "Further studies are warranted to elucidate the potential mechanisms for the effects of long-term yogurt intake on colorectal carcinogenesis."
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
ASCO: Disease-Free Survival Prolonged With Exercise Program in Colon Cancer
TUESDAY, June 3, 2025 -- For patients with resected colon cancer who have completed adjuvant chemotherapy, a three-year structured exercise program results in significantly longer...
ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC
FRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus...
Multitarget Stool DNA Tests More Costly Than FIT for Colorectal Cancer Detection
WEDNESDAY, May 14, 2025 -- Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.